Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Vertex Pharmaceuticals: Strong Pipeline and Strategic Growth Propel ‘Buy’ Rating
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Vertex Pharmaceuticals: Strong Future Potential with Key Drug Launches and Underappreciated Opportunities
Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
money.rediff5d
Lupin Gets USFDA Approval for Generic Cystic Fibrosis Treatment
Lupin receives USFDA approval for its generic version of Ivacaftor oral granules, a treatment for cystic fibrosis. The ...
Barchart on MSN5d
Vertex Pharmaceuticals Earnings Preview: What to Expect
Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and ...
Nasdaq5d
Vertex Pharmaceuticals Earnings Preview: What to Expect
Vertex Pharmaceuticals exceeded earnings expectations in the last quarter, driven by strong demand for its cystic fibrosis therapies and operational efficiency. In fiscal 2024, analysts expect the ...
Lupin gets USFDA nod for generic cystic fibrosis treatment medicine
India has the potential to increase exports of organic products up to Rs 20,000 crore in the next three years, Commerce and ...
ORG Partners LLC Has $41,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...
ndtvprofit5d
Lupin Receives Tentative USFDA Approval For Generic Ivacaftor Oral Granules
These generic granules are equivalent to Vertex Pharmaceuticals' 'Kalydeco' oral granules in the same strengths.